Clinicopathologic features of pediatric oligodendrogliomas: A series of 50 patients

American Journal of Surgical Pathology

Volumn 38, Issue 8, 2014, Pages 1058-1070

  Rodriguez, Fausto J ^a,b   Tihan, Tarik ^c   Lin, Doris ^c   McDonald, William ^d   Nigro, Janice ^c,e   Feuerstein, Burt ^e   Jackson, Sadhana ^b   Cohen, Kenneth ^b   Burger, Peter C ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Hospital Pathology Associates   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

1p19q; brain tumor; IDH1; Oligodendroglioma; pediatric glioma

Indexed keywords

ADOLESCENT; ARTICLE; BRAIN TUMOR; CHILD; CHROMOSOME 1; CHROMOSOME DELETION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN MEIER METHOD; MALE; MORTALITY; OLIGODENDROGLIOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KAPLAN-MEIER ESTIMATE; MALE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84904563334     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000221     Document Type: Article

References (54)

1. Bowers DC, Mulne AF, Weprin B, et al. Prognostic factors in children and adolescents with low-grade oligodendrogliomas. Pediatr Neurosurg. 2002;37:57-63.
2. Bruggers C, White K, Zhou H, et al. Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature. J Pediatr Hematol Oncol. 2007;29:319-322.
3. Dohrmann GJ, Farwell JR, Flannery JT. Oligodendrogliomas in children. Surg Neurol. 1978;10:21-25.
4. Favier J, Pizzolato GP, Berney J. Oligodendroglial tumors in childhood. Childs Nerv Syst. 1985;1:33-38.
5. Furtado SV, Venkatesh PK, Ghosal N, et al. Clinical and radiological features of pediatric cerebellar anaplastic oligodendrogliomas. Indian J Pediatr. 2011;78:880-883.
6. Kreiger PA, Okada Y, Simon S, et al. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol. 2005;109:387-392.
7. Myal Y, Del Bigio MR, Rhodes RH. Age-related differences in 1p and 19q deletions in oligodendrogliomas. BMC Clin Pathol. 2003;3:6.
8. Packer RJ, Sutton LN, Rorke LB, et al. Oligodendroglioma of the posterior fossa in childhood. Cancer. 1985;56:195-199.
9. Peters O, Gnekow AK, Rating D, et al. Impact of location on outcome in children with low-grade oligodendroglioma. Pediatr Blood Cancer. 2004;43:250-256.
10. Raghavan R, Balani J, Perry A, et al. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol. 2003;62:530-537.
11. Razack N, Baumgartner J, Bruner J. Pediatric oligodendrogliomas. Pediatr Neurosurg. 1998;28:121-129.
12. Rizk T,Mottolese C, Bouffet E, et al. Cerebral oligodendrogliomas in children: an analysis of 15 cases. Childs Nerv Syst. 1996;12:527-529.
13. Suri V, Jha P, Agarwal S, et al. Molecular profile of oligodendrogliomas in young patients. Neuro-oncol. 2011;13:1099-1106.
14. Wang KC, Chi JG, Cho BK. Oligodendroglioma in childhood. J Korean Med Sci. 1993;8:110-116.
15. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3:709-722.
16. Camelo-Piragua S, Jansen M, Ganguly A, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol. 2011;70:110-115.
17. Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lowergrade glioma. Oncotarget. 2012;3:1194-1203.
18. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/ IDH2 and TP53 mutations. Acta Neuropathol. 2012;124:615-625.
19. Nguyen DN, Heaphy CM, de Wilde RF, et al. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol. 2013;23:237-243.
20. Zhang J,Wu G,Miller CP, et al.Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45: 602-612.
21. Ramkissoon LA, Horowitz PM, Craig JM, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci USA. 2013;110:8188-8193.
22. O'Brien DF, Farrell M, Delanty N, et al. The Children's Cancer and Leukaemia Group guidelines for the diagnosis and management of dysembryoplastic neuroepithelial tumours. Br J Neurosurg. 2007;21: 539-549.
23. Harada S, Henderson LB, Eshleman JR, et al. Genomic changes in gliomas detected using single nucleotide polymorphism array in formalin-fixed, paraffin-embedded tissue: superior results compared with microsatellite analysis. J Mol Diagn. 2011;13:541-548.
24. Hatanpaa KJ, Burger PC, Eshleman JR, et al. Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest. 2003;83:419-428.
25. Jenkins RB, Curran W, Scott CB, et al. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol. 2001;24:506-508.
26. Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001;158:1253-1262.
27. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344-350.
28. Padovani L, Colin C, Fernandez C, et al. Search for distinctive markers in DNT and cortical grade II glioma in children: same clinicopathological and molecular entities? Curr Top Med Chem. 2012;12:1683-1692.
29. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006;65:988-994.
30. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861.
31. Pollack IF, Hamilton RL, Sobol RW, et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst. 2011;27:87-94.
32. Snuderl M, Eichler AF, Ligon KL, et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009; 15:6430-6437.
33. Pollack IF, Finkelstein SD, Burnham J, et al. Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort. Pediatr Neurosurg. 2003;39:114-121.
34. Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol. 2013;26:922-929.
35. Clark KH, Villano JL, Nikiforova MN, et al. 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol. 2013;39:706-717.
36. Pollack IF, Claassen D, al-Shboul Q, et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg. 1995;82:536-547.
37. McDonald JM, See SJ, Tremont IW, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005;104:1468-1477.
38. Zlatescu MC, TehraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001;61:6713-6715.
39. Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, et al. Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology. 2004;63:2360-2362.
40. Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012;18:2490-2501.
41. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29:4482-4490.
42. Hewer E, Beck J, Vassella E, et al. Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion. Neuropathology. 2013;34:32-38.
43. Mittelbronn M, Wolff M, Bultmann E, et al. Disseminating anaplastic brainstem oligodendroglioma associated with allelic loss in the tumor suppressor candidate region D19S246 of chromosome 19 mimicking an inflammatory central nervous system disease in a 9-year-old boy. Hum Pathol. 2005;36:854-857.
44. Thom M, Toma A, An S, et al. One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J Neuropathol Exp Neurol. 2011;70:859-878.
45. Azzarelli B, Miravalle L, Vidal R. Immunolocalization of the oligodendrocyte transcription factor 1 (Olig1) in brain tumors. J Neuropathol Exp Neurol. 2004;63:170-179.
46. Komori T, Arai N. Dysembryoplastic neuroepithelial tumor, a pure glial tumor? Immunohistochemical and morphometric studies. Neuropathology. 2013;33:459-468.
47. Takahashi H, Kakita A, Tomikawa M, et al. Oligodendroglioma (WHO grade I) in a young epilepsy patient: a specific entity lying within the spectrum of dysembryoplastic neuroepithelial tumor? Neuropathology. 2013;33:645-651.
48. Gonzales M, Dale S, Susman M, et al. Dysembryoplastic neuroepithelial tumor (DNT)-like oligodendrogliomas or Dnts evolving into oligodendrogliomas: two illustrative cases. Neuropathology. 2007;27:324-330.
49. Agamanolis DP, Katsetos CD, Klonk CJ, et al. An unusual form of superficially disseminated glioma in children: report of 3 cases. J Child Neurol. 2012;27:727-733.
50. Gardiman MP, Fassan M, Nozza P, et al. Diffuse leptomeningeal glioneuronal tumours: clinico-pathological follow-up. Pathologica. 2012;104:428-431.
51. Rhiew RB, Manjila S, Lozen A, et al. Leptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma. Acta Neurochir (Wien). 2010;152:1425-1429.
52. Rodriguez FJ, Perry A, Rosenblum MK, et al. Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. Acta Neuropathol. 2012;124:627-641.
53. Schniederjan MJ, Alghamdi S, Castellano-Sanchez A, et al. Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry. Am J Surg Pathol. 2013;37:763-771.
54. Rossi S, Rodriguez FJ, Mota RA, et al. Primary leptomeningeal oligodendroglioma with documented progression to anaplasia and t(1;19)(q10;p10) in a child. Acta Neuropathol. 2009;118:575-577.